Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Gsk Plc LSE:GSK London Ordinary Share GB00BN7SWP63 ORD 31 1/4P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -13.40 -0.9% 1,479.00 1,478.20 1,478.80 1,502.00 1,477.80 1,500.00 1,030,147 09:26:38
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 34,114.0 5,442.0 87.6 16.9 60,156

Gsk Share Discussion Threads

Showing 30876 to 30900 of 31525 messages
Chat Pages: Latest  1237  1236  1235  1234  1233  1232  1231  1230  1229  1228  1227  1226  Older
DateSubjectAuthorDiscuss
19/8/2022
13:57
AZN very near a new all time high
netcurtains
19/8/2022
13:38
PUBLISHED: 22:19, 17 August 2022 ..... overreaction
tradermichael
19/8/2022
12:52
from today's Mail:-
"Haleon is just the latest in a line of IPO flops damaging the reputation of the London Stock Exchange"


hTTps://www.dailymail.co.uk/money/comment/article-11120833/ALEX-BRUMMER-Haleons-IPO-flop-damages-London-Stock-Exchange.html

jonjoneil
19/8/2022
09:57
Added again.Volatility is getting more muted.Hoping the 1371p last week was the capitulation trade.Time will tell.Recovery or more falls to come?
redbaron10
19/8/2022
08:22
We're ex-dividend now and the price is up a bit.
netcurtains
18/8/2022
16:33
I think I am right in saying that there has always been some mild background concern that in turning off gastric acid there might be some small risk of inducing gastric/lower oesophageal cancer , as for the achlorhydria and gastric cancer with Pernicious Anaemia. A gastroenterologist may be able to confirm or refute this suspicion. Granted litigation in relation to Zantac maybe in due course we might see moves against the PPI group of drugs which have largely replaced Zantac and its like.
mayers
18/8/2022
16:07
Not looking good for GSK. Staff will start leaving in their droves as the ship is rudderless and sinking fast. They need a new Captain Kirk to take the Enterprise onwards and away.!
rocketblast
18/8/2022
15:20
EI
I guess the problem might be, if any link to current issue is found to this previous court case:

Https://www.justice.gov/opa/pr/glaxosmithkline-plead-guilty-and-pay-3-billion-resolve-fraud-allegations-and-failure-report

Who was MD in 2012?

netcurtains
18/8/2022
14:17
As harsh as the US judicial system can be for non US companies, they do don't usually seek to bankrupt corporates - if there are large amounts to be paid out,
which is far from certain.

The only big exception I can think of is asbestos law suits,
which destroyed many companies.

LSE listed SMIN is one of the survivors and is still dealing with annual asbestos claims all these years later.

essentialinvestor
18/8/2022
14:03
Couldn't resist £14 so dipped toe in
my retirement fund
18/8/2022
11:38
AZN gone blue....

Its about time GSK followed.

netcurtains
18/8/2022
10:42
So, let's hope that they can handle a massive production program.
tradermichael
18/8/2022
10:02
Jonjonell, that is really interesting thank you. in 2020 there were 241mln cases of malaria world wide. with 95% of cases in Africa.

https://www.who.int/news-room/fact-sheets/detail/malaria

18mln doses is a drop in the ocean and the potential for upside in this vaccine is equal to if not more than the shingles vaccine in China.

berny3
18/8/2022
09:23
GSK lands first-ever UNICEF contract for malaria vaccine

hTTps://endpts.com/gsk-lands-first-ever-unicef-contract-for-malaria-vaccine-worth-170m/

jonjoneil
18/8/2022
07:54
Hey net, my choice of words was poor and I should have said something like "and it's clear GSK and others will defend these unfounded accusations if necessary."

Agree it's easy to file cases but far harder to win them.

tuftymatt
18/8/2022
06:34
It doesn't appear if GSK needs to fight. The "no win no fee" type law would not have bothered dropping out unless it was a totally hopeless case. It's pretty clear GSK is now in the clear from all legal cases relating to the DERIVATIVE versions of Zantac..... And probably in the clear from the real Zantac too.
netcurtains
18/8/2022
05:57
A fair write up and thanks una.

As well all know the market hates uncertainty so in this current climate it could drift lower in line with the general markets, excluding the obvious divi drop.

I would not expect any significant drop though as the news is now out there in my opinion and GSK and others will fight this hard.

tuftymatt
18/8/2022
05:52
also this in The Times today offers some insight in to the story yesterday about the first case being withdrawn

"Shares in Haleon fell to fresh lows and GSK, which spun the company off last month, weakened over concerns about potential liabilities relating to Zantac after a report that generic drug companies had reached a settlement in a US legal case (Alex Ralph writes). It emerged on Tuesday that the plaintiff in the first lawsuit due to go to trial in Illinois had dropped his case. GSK, a defendant in the case, welcomed the decision. A lawyer for the claimant, however, said her client had decided not to pursue the case at this time because of complications from the removal of his oesophagus. Bloomberg reported that generic drugmakers Teva, Perrigo, Sun Pharma and Dr Reddy's Laboratories agreed to a combined settlement of more than $500,000 with the claimant after he alleged Zantac, a medication for heartburn, caused his oesophageal cancer. Haleon, the former consumer healthcare joint venture of GSK and Pfizer, has said it is not a party to any Zantac claims and conditions would need to be met before it was required to indemnify GSK and Pfizer of any liabilities. Haleon closed down 10¾p at 258½p and GSK fell 9½p to £14.15½p."

unastubbs
18/8/2022
05:47
Shares Magazine today on the situation

hTTps://ibb.co/YRnkJN6

unastubbs
17/8/2022
23:37
How about 1390.6? No idea, but somebody has to take up the challenge!!
redbaron10
17/8/2022
15:32
Any guesses on opening price tomorrow. If the price discounts the dividend, I will use that as my reentry point. Otherwise I will continue monitoring from the sidelines.
I sold on a whim (coin toss), and I will use equal vaguery to get back in. The longer I try to reason my way back the longer I will stay out.

jonjoneil
17/8/2022
14:13
There's no cut in dividend 56.5 to 65p per annum. Around 4.65% yield.


There are better yields out there but when you consider how defensive this sector is, I am happy with this yield. Personally expect choppy markets ahead.


Have loaded up here this week, average price Around 1405. Will hold for a while. Not worried about litigation risk at this price point- it's all in the price.

wallywoo
17/8/2022
13:35
GSK PLC said Wednesday that momelotinib's new drug application, or NDA, has been accepted by the U.S. Food and Drug Administration for the treatment of myelofibrosis.

The U.K. pharmaceutical company said the FDA assigned a Prescription Drug User Fee Act, or PDUFA, action date of June 16, 2023.

The PDUFA refers to the date by which the agency's review process must be completed.

The FTSE 100-listed company said the NDA is based on results from key Phase 3 trials which met all primary and key secondary endpoints, and added that momelotinib wasn't currently approved in any market.

tradermichael
17/8/2022
13:33
16.25p for Q2
tradermichael
17/8/2022
13:33
Also topped up at £14.50 and £14 in last few days and tend to agree with NY boy although I'd hope for a recovery a little quicker than his timeframe :)It's a shame to see the poor sentiment from the days of old GSK carry over to new GSK. Yes, I would have expected a reaction to the litigation news (although I think the company's strong rebuttal plus absence of any real evidence augurs for a good outcome in the end) but the scale of it, to me anyway, tells me the investor community are still very negative on this company.They need a lot of things to go right over the next few years to change that but here's hoping.
rikky72
Chat Pages: Latest  1237  1236  1235  1234  1233  1232  1231  1230  1229  1228  1227  1226  Older
Your Recent History
LSE
GSK
Gsk
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20221208 09:41:40